Rockefeller Capital Management
XENE icon

Rockefeller Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Rockefeller Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.1K Hold
200
– – ﹤0.01% 3938
2026
Q1 		$11.6K Sell
200
-900
-82% -$41.5K ﹤0.01% 3933
2025
Q4 		$49.3K Buy
1,100
+900
+450% +$37.8K ﹤0.01% 3079
2025
Q3 		$8.03K Buy
+200
New +$7.04K ﹤0.01% 3734

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rockefeller Capital Management's XENE Position: Q2 2026 in Review

Rockefeller Capital Management held its Xenon Pharmaceuticals (XENE) position steady in Q2 2026 at 200 shares worth $12.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3938.

Rockefeller Capital Management first reported a position in XENE in Q3 2025 and has held it in 4 quarters since. The position peaked at $49.3K in Q4 2025. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Rockefeller Capital Management held 200 shares of Xenon Pharmaceuticals worth $12.1K as of Q2 2026.
  • Rockefeller Capital Management left its Xenon Pharmaceuticals share count unchanged in Q2 2026.
  • Xenon Pharmaceuticals made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3938 holding.
  • Rockefeller Capital Management first reported a position in Xenon Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Rockefeller Capital Management's Xenon Pharmaceuticals position peaked at $49.3K in Q4 2025.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.